Finding a winner in VX-445, Vertex hustles CF combo to regulators on both sides of Atlantic
The verdict is in from Vertex’s clinical team.
The biotech was presented with a pleasant dilemma in March when a cocktail for cystic fibrosis mixing VX-445, tezacaftor and ivacaftor passed Phase III with flying colors, matching the results they got for VX-659 with the other two drugs, also known as Symdeko and Kalydeco. That left observers hanging as to which combo will head to regulators.
Vertex ultimately decided to go with VX-445 — after reviewing some more data it’s disclosing today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.